<DOC>
	<DOC>NCT00424021</DOC>
	<brief_summary>AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study NCT00046319, "A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to Severe Pulmonary Arterial Hypertension".</brief_summary>
	<brief_title>Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Must have completed Visit 14/Week 24 of the NCT00046319 study. Women of childbearing potential must have a negative urine pregnancy test at the Screening/Enrollment Visit and agree to use a reliable double barrier method of contraception until study completion and for &gt;=4 weeks following their final study visit. Must have completed the Downtitration Period of NCT00046319 prior to enrollment in AMB220E and will meet the following additional criteria: Subjects with a diagnosis of HIV must have stable disease status at the time of Screening/Enrollment. Must be stable on conventional therapy for PAH for &gt;=4 weeks prior to the Screening Visit. Chronic prostanoid therapy, or other investigational prostacyclin derivative within 4 weeks prior to the Screening Visit. Intravenous inotrope use within 2 weeks prior to the Screening Visit. Females who are pregnant or breastfeeding. Contraindication to treatment with an endothelin receptor antagonist (ERA).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>